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INTRODUCTION
Gadoxetate disodium (Eovist/Primovist; Bayer Healthcare, 
Berlin, Germany) is a recently introduced and valuable 
addition to magnetic resonance (MR) contrast agents for 
liver imaging. It enables vivid hepatobiliary phase imaging 
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that reflects its specific hepatocyte uptake, it and can 
also provide dynamic phase imaging that is similar to 
the results from using conventional extracellular contrast 
agents (1, 2). Although hepatobiliary phase images of 
gadoxetate disodium-enhanced MR offer new opportunities 
for detecting and characterizing focal hepatic lesions, 
arterial phase imaging remains critical for the diagnosis 
and treatment response evaluation of hepatic tumors such 
as hepatocellular carcinomas (HCCs) (3-5). Unfortunately, 
arterial-phase images of gadoxetate-enhanced liver MR 
are sometimes unsatisfactory because of weak arterial 
enhancement (6, 7) and respiratory motion artifacts caused 
by so-called transient severe motion (TSM) (6-10). In our 
article, we review the challenges in obtaining high-quality 
arterial-phase images and then explore possible solutions 
for optimizing the arterial-phase imaging of gadoxetate 
disodium-enhanced liver MR.
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Challenges for Arterial-Phase Imaging
The smaller administered volume and gadolinium 
content of gadoxetate disodium compared with those of 
conventional extracellular MR contrast and the frequent 
occurrence of TSM can interfere with obtaining optimal 
arterial-phase images with gadoxetate disodium-enhanced 
MR (Table 1). 
Small Administered Volume and Gadolinium Content
The standard gadoxetate-disodium injection dose 
is only half of that of conventional extracellular MR 
contrast (0.1 mL/kg of gadoxetate disodium vs. 0.2 mL/
kg of gadopentetate dimeglumine) (11). The gadolinium 
content of a standard dose of gadoxetate-disodium is only 
a quarter of that of conventional extracellular contrast 
(0.025 mmol/kg of gadoxetate disodium vs. 0.1 mmol/kg 
of Gd-DTPA) (11). This recommended dose of gadoxetate 
disodum is based on a dose-finding study (12) that 
compared gadoxetate disodium given at three different 
gadolinium doses (0.0125, 0.025, and 0.05 mmol/kg) 
with gadopentetate dimeglumine at a standard gadolinium 
content of 0.1 mmol/kg. Compared with gadopentetate 
dimeglumine, similar enhancement characteristics of benign 
and malignant lesions during the first three minutes after 
contrast injection were found at 0.025 and 0.05 mmol/kg of 
gadoxetate disodium but not at the lowest dose of 0.0125 
mmol/kg of (12).
In spite of the higher T1 relaxivity of gadoxetate 
disodium measured in human blood compared with other 
conventional extracellular MR contrasts (13, 14), this 
smaller administered volume and gadolinium content causes 
difficulties in obtaining consistently optimal arterial-
phase images. The smaller contrast volume can potentially 
shorten the enhancement duration of the contrast bolus 
and decrease the magnitude of the peak enhancement of 
the contrast bolus (Fig. 1) (15, 16). The lower gadolinium 
content can also result in a lower magnitude of the peak 
enhancement of the contrast bolus (15, 16). The effects of 
the small administered volume and gadolinium content are 
reflected in the weak arterial enhancement on images (6, 7) 
and can pose challenges to capturing optimal arterial-phase 
imaging (10). Recent studies revealed that weak arterial 
enhancement can possibly affect the lesion conspicuity 
of hypervascular tumors such as HCCs and focal nodular 
hyperplasias during the arterial phase of gadoxetate-
enhanced liver MR imaging in comparison with gadobenate 
dimeglumine-enhanced MR imaging (17, 18).
Transient Severe Motion 
Recent work suggested that the image quality of the 
arterial phase in gadoxetate-enhanced liver MR is more 
Table 1. Challenges and Solutions for Optimal Arterial Phase Images with Gadoxetate-Enhanced Liver MRI
Challenges Causes Solutions
Weak arterial enhancement
Smaller injection volume and 
  gadolinium content
Slow injection rate of 1 mL/sec
Increased dose at fixed dose of 10 mL
Bolus detection method or multiple arterial-phase image 
  acquisition with fixed delay method
MR image acquisition at 3T 
Subtraction images
Respiratory motion artifacts Transient severe motion (TSM)
Consideration of risk factors to develop TSM
Multiple arterial-phase images
Motion insensitive MR sequences 
Fig. 1. Simulated contrast enhancement curve of abdominal 
aorta and liver. Small amount of administered volume and gadolini-
um content of gadoxetate disodium (red line) can potentially shorten 
enhancement duration of contrast bolus and decrease magnitude of 
peak enhancement of contrast bolus compared with favorable contrast 
bolus curve (green line). This shape of gadoxetate disodium curve (red 



















0 25 50 75 100 125 150 175 200
Time (sec)
Gadoxetate disodium
A favorable contrast bolus
1209
Arterial Phase of Gadoxetate Disodium-Enhanced Liver MR
Korean J Radiol 16(6), Nov/Dec 2015kjronline.org
commonly deteriorated by the TSM phenomenon than other 
gadolinium-based contrast agents (Fig. 2) (8, 19). The 
reported incidence ranges from 10.7 to 18% (8, 19-21), 
which suggests that over 10% of gadoxetate-enhanced liver 
MR examinations may have unsatisfactory arterial-phase 
images related to this artifact. As the name “TSM” implies, 
this artifact occurs in a very brief duration and is usually 
confined to the arterial phase (8, 19-22). 
The cause of this phenomenon remains unclear, although 
a number of recent articles have suggested possible risk 
factors related to the occurrence of TSM (19, 21, 22). This 
artifact can potentially limit the advantages of gadoxetate-
enhanced magnetic resonance imaging (MRI), although the 
impact of TSM on the diagnostic performance of gadoxetate-
enhanced liver MRI has not been well demonstrated. 
Thus, strategies to minimize the effects of TSM need to be 
explored and are now an area of active research.
Optimization Strategies
To compensate for the potential drawbacks of arterial-
phase gadoxetate-enhanced liver MR imaging, i.e., weak 
arterial enhancement, difficulty capturing optimal arterial-
phase images, and frequent occurrence of TSM, we can 
modify the injection protocol techniques to determine 
optimal scan timing and MR image acquisition methods 
(Table 1).
Modification of Injection Protocols 
Given the half-sized injection volume and the quarter 
Fig. 2. 68-year-old man with respiratory motion artifacts.
This arterial phase image of gadoxetate-enhanced liver MR (B) is severely contaminated by respiratory motion artifacts related to TSM, whereas 
noncontrast (A), portal venous (C), and hepatobiliary (D) phase images look fine. Owing to presence of TSM, arterial hypervascularity of lesion 
in right lobe of liver (arrows) cannot be exactly evaluated on this MR image, although lesion (arrows) is clearly defined on non-contrast (A), por-
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content of gadolinium compared with conventional 
extracellular MR contrast, the contrast bolus of gadoxetate-
enhanced MR is likely to have a narrower shape and 
lower magnitude of peak enhancement (Fig. 1) (14-16). 
It would be helpful to stretch out the duration of high-
level aorta enhancement in the bolus shape to achieve 
proper arterial-phase timing and contrast-to-noise ratios 
of arterial hypervascular tumors such as HCC (Fig. 1). In 
order to obtain a favorable bolus shape, the following three 
approaches have been suggested in previous publications: 
1) a decreased injection rate of 1 mL/sec; 2) an increased 
amount of gadoxetate; and 3) dilution of gadoxetate 
disodium by adding saline. 
Prior reports (11, 14, 23-25) compared the effect of 
a decreased injection rate of 1 mL/sec to those of a 
higher injection rate of 2 or 3 mL/sec commonly used for 
extracellular MR contrast. These studies (11, 14, 23-25) 
demonstrated that the slower injection rate is beneficial 
not only in stretching the bolus but also in increasing 
the magnitude of the peak enhancement. This increased 
magnitude may look somewhat counterintuitive when we 
consider the contrast enhancement curve on CT (15, 16), 
in which an increased injection rate results in increased 
arterial enhancement. This discrepancy can be explained by 
the following two factors. First, because the bound fraction 
of gadoxetate disodium has a higher relaxivity than the 
unbound fraction (13), a slow injection rate likely permits 
sufficient time for gadoxetate disodium to be mixed with 
human blood and bound to plasma protein. Second, the 
relationship between MR signal intensity and gadolinium 
concentration is not linear, which might be responsible for 
saturation effects in a highly concentrated bolus related 
to T2* shortening whereas the relationship between CT 
attenuation and iodine concentration is linear. Nonetheless, 
excessive reduction of the injection rate may not have a 
positive effect on arterial-phase imaging: a previous study 
(26) that compared the injection rates of 0.5 mL/sec and 
1 mL/sec showed a lower HCC contrast-to-noise ratio at 
an injection rate of 0.5 mL/sec than those of 1 mL/sec, 
although the result was not significant. Thus, given the 
results from previous work, a decreased injection rate of 1 
mL/sec seems to the best rate for optimal arterial-phase 
imaging using gadoxetate disodium. 
Although 0.025 mmol/kg of gadoxetate disodium is the 
on-label approved dose, the dose of gadoxetate disodium 
for optimal arterial-phase images is still under debate. 
Administration of gadoxetate disodium at a higher off-label 
dose such as a fixed dose of 10 mL (9, 10, 27) or 20 mL (19) 
or a double dose (0.5 mmol/kg) (28) has been described 
in previous work. This higher dose would prolong the peak 
arterial perfusion time, which could help to overcome 
the temporal mismatch, increase the degree of the peak 
aortic enhancement, and consequently improve liver-to-
lesion contrast on arterial-phase images (14, 28). However, 
the safety of this higher off-label dose has not been 
demonstrated. A recent study reported that when a fixed 
20-mL dose of gadoxetate disodium was used, TSM occurred 
more frequently than when the standard dose was used (19). 
Thus, even though administering gadoxetic acid at a fixed 
dose of 10 mL seems to be preferred in many institutions (9, 
10, 27), it should be noted that it is an off-label dose. 
Diluting gadoxetate disodium with saline has been 
proposed as a possible option to help stretch the contrast 
bolus (29) because can possibly have similar effects to 
those of a decreased injection rate on a bolus shape. 
However, previous research (11) has demonstrated limited 
evidence of benefits. Given a risk of contamination though 
the mixing process, dilution is not well regarded as a 
practical solution for improving the quality of arterial-phase 
imaging.
Techniques for Optimal Scan Timing 
Gadoxetate disodium-enhanced liver MR demands 
more precise timing for hepatic arterial-phase images 
because of the narrower contrast bolus compared with 
conventional extracellular MR contrast. Because a simple 
fixed delay method is prone to timing error with the 
influence of individual variation or injection protocol, it 
is not recommended in gadoxetate disodium-enhanced 
liver MRI. Previous work showed that simple fixed delay 
was inferior to bolus tracking (23, 30) or test bolus (29) 
in capturing proper hepatic arterial-phase timing, aortic 
enhancement, and lesion-to-liver contrast in hypervascular 
HCCs. One study suggested that the optimal scan delay for 
hypervascular HCCs in gadoxetate-enhanced arterial-phase 
images is 7–12 seconds after the peak aortic enhancement 
at an injection rate of 1 mL/sec (31). One possible 
drawback of manual bolus tracking is its operator-dependent 
nature. If the procedure is conducted by well-trained 
technicians, the best results can be achieved; optimal 
arterial-phase images were obtained in 91.7% of patients 
using manual bolus-tracking (23). The recent introduction 
of an automated bolus detection method appears to be 
promising for solving the potential problems with manual 
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bolus tracking (32). Applying a test bolus method may be 
limited by the small amount of gadoxetate disodium and 
rapid uptake by hepatocytes, which can possibly leave an 
insufficient amount of the contrast and thus deteriorate 
lesion-to-liver contrast (10). Another option can be 
acquiring multiple (usually three) arterial-phase images 
Fig. 3. 71-year-old man who underwent liver MRI both at 1.5T and 3T in one-week interval.
On arterial phase images at 3T (A, B), four more lesions (arrows) as well as large hypervascular tumor (arrowheads) are additionally detected, 
whereas on 1.5T MR images (C, D), only main lesion (arrowheads) is found. Lesions look more conspicuous on 3T MR images (A, B) than they 
do 1.5T MR images (C, D). Non-enhanced follow-up CT images (E, F) after transarterial chemoembolization demonstrate lipidol uptakes on four 
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with a fixed time delay (20). In addition to a high rate of 
adequate arterial-phase images (98%) (20), this method 
can provide robustness to TSM and the availability of more 
than one arterial-phase value, which can possibly provide 
a more precise assessment of the arterial enhancement 
of focal hepatic lesions. However, because of the higher 
temporal resolution required for multiple arterial-phase 
images, reducing the spatial resolution and the signal-to-
noise ratio results in inevitable trade-offs (20). 
Therefore, simple fixed delay is discouraged for 
determining optimal arterial-phase scan timing for 
gadoxetate-enhanced liver MR. Bolus tracking or acquiring 
multiple (usually three) arterial-phase images with a fixed 
time delay can be better strategies.
Optimizing Image Acquisition
Currently, a fat-suppressed three-dimensional (3D), 
T1-weighted gradient echo (GRE) sequence is widely 
accepted as a key sequence for liver dynamic MR because 
it provides satisfactory spatial resolution, adequate signal-
to-noise ratio and a temporal resolution that is sufficient 
to be performed during breath holding (22, 33, 34). 
Volumetric interpolated breath hold examination (VIBE; 
Siemens Healthcare, Erlangen, Germany), liver acquisition 
volume acceleration (LAVA; GE Healthcare, Milwaukee, 
WI, USA), and enhanced T1-high resolution isotropic 
volume excitation (eTHRIVE; Philips Healthcare, Best, the 
Netherlands) are commonly used 3D GRE sequences for liver 
MR examinations (35). Most institutions employ parallel 
acquisition techniques decrease acquisition time or improve 
spatial resolution (36, 37). The use of multiple arterial-
phase acquisitions (20), controlled aliasing in parallel 
imaging results in higher acceleration (CAIPIRINHA) VIBE 
and radial k-space sampling 3D GRE sequence (as known as 
Radial-VIBE) (30, 38-40) can be considered techniques to 
improve the quality of arterial-phase images. 
Clinical use of 3T MR imaging has evolved rapidly over 
the past decade. The major advantage of 3T is a nearly 
two-fold signal gain in signal-to-noise ratio, which 
allows higher signal, higher spatial resolution or shorter 
examination times in liver imaging compared with 1.5T 
(41, 42). In addition, theoretically substantial gains can 
be anticipated in post-contrast T1-weighted imaging at 
3T. T1 relaxation times are prolonged as the magnetic field 
increases; however, the T1 relaxation times of gadolinium 
contrast increase minimally whereas the values of hepatic 
tissue can lengthen substantially (41, 42). Thus, it likely 
leads to an apparent contrast gain on high-field MR 
imaging, which brings higher lesion-to-liver contrast in 
hypervascular tumors such as HCC in arterial-phase imaging 
(Fig. 3). However, there is a paucity of data that compare 
the arterial-phase image quality of gadoxetate disodium-
enhanced liver MRI in different field strengths. Although 
higher field imaging has some disadvantages including 
specific absorption rate limitation, increased susceptibility 
artifacts, field inhomogeneity and standing wave artifacts, 
we believe that 3T MR imaging is a promising approach to 
improving the arterial-phase image quality of gadoxetate 
disodium-enhanced liver MRI. Given improved signal-to-
noise ratio and better lesion-to-liver contrast, additional 
studies are warranted to prove the potential advantages 
of 3T on arterial-phase images of gadoxetate-disodium 
enhanced liver MRI for detection and characterization, 
especially in small lesions.
Minimize Transient Severe Motion Severity
In order to develop strategies to avoid TSM, it is critical 
to identify TSM causes and risk factors. Unfortunately, TSM’s 
causes and pathophysiology have yet to be elucidated. 
Recent studies suggested a number of possible risk factors 
for TSM: a previous episode of TSM (21, 22), an off-label 
administered volume of 20-mL fixed dose at 2 mL/s (19), 
a history of allergy to iodinated contrast for CT (21), low 
body weight (19), and chronic obstructive lung disease 
(COPD) (19). However, some of the risk factors are still in 
question because the results from the published studies 
were not consistent; low body weight (19, 21) and the 
presence of COPD (21, 22) were not identified as significant 
risk factors in some studies. 
Some studies described ringing artifacts as a different 
type of artifact that can also occur during the arterial 
phase of gadoxetate disodium-enhanced liver MRI because 
of rapid changes in the contrast concentration while 
obtaining the data in the center of the k-space (43). TSM 
ringing artifacts and motion artifacts may have similar 
appearances on images, and some earlier studies did not 
seem to specifically describe these artifacts. However, by 
definition, ringing artifacts are centered on the vessels and 
confined to the abdomen, whereas TSM motion artifacts are 
centered on the abdominal wall and can extend outside of 
it (22, 43). In our experience, TSM motion artifacts seem to 
be more commonly encountered and more problematic than 
ringing artifacts in clinical practice. 
In patients with high risk factors for TSM, it could 
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be better to consider using other contrast agent in 
cases in which optimal arterial-phase images as well as 
hemodynamic information are crucial for characterizing 
lesions, for example, when we evaluate a lesion that is 
suspicious for hepatic hemangioma. However, in cases in 
which hepatobiliary phase images are essential, such as 
detecting hepatic metastasis in patients with underlying 
malignancy, we can choose gadoxetate disodium as the MR 
contrast at the same time that we attempt to minimize the 
effects of TSM on arterial-phase images. The use of multiple 
arterial-phase acquisition can overcome the effect of TSM 
because at least one arterial-phase image can be obtained 
well-timed and not compromised by motion in 81% of 
patients with TSM (20). The use of motion-insensitive 
sequences such as CAIPIRINHA VIBE and radial-VIBE can be 
promising (30, 38-40).
Subtraction Images
Owing to technical advances in image registration 
techniques, subtraction images have increasingly become 
an integral part of liver MRI in many hospitals (44, 45). As 
was demonstrated with other gadolinium contrast agents 
(44, 45), subtraction images between the unenhanced 
and arterial phase using gadoxetate disodium can be 
more beneficial for depicting the arterial enhancement 
of lesions than visual image comparison, which resulted 
in higher diagnostic performance in small HCCs less 
than 3 cm (46). Subtraction images would be helpful for 
overcoming the potential weak arterial enhancement of 
gadoxetate disodium-enhanced liver MRI. However, one of 
the limitations in subtraction images is the susceptibility 
to misregistration artifacts because the respiratory motion 
causes erroneous co-registration between source images in 
the subtraction process (46). We should keep in mind that 
misregistration artifacts can yield pseudoenhancement of 
lesions and thus overdiagnosis of HCC (44).
CONCLUSION
Gadoxetate disodium-enhanced MR can greatly improve 
the detection and characterization of focal liver lesions 
because of its distinctive properties as a dual-function 
contrast agent. However, these advantages are sometimes 
diminished by the poor quality of arterial-phase imaging 
owing to weak arterial enhancement, inappropriate scan 
timing, and severe motion artifacts. The main causes of 
these difficulties were explained by the small injection 
volume and gadolinium content as well as the occurrence 
of TSM in more than 10% of patients. In this article, 
we reviewed possible strategies for overcoming these 
problems. Many institutions employ a modified injection 
protocol with a slow injection rate of 1 mL/sec and a fixed 
increased dose of 10 mL to obtain a favorable contrast 
bolus. To determine the optimal arterial-phase timing, 
bolus detection or multiple arterial-phase acquisition with 
a fixed delayed method is a preferred option. In patients 
at high risk for developing TSM, i.e., a previous episode 
of TSM (21, 22), a higher off-label administered volume 
of 20-mL fixed dose at 2 mL/s (19), a history of allergy to 
iodinated contrast for CT (21), low body weight (19), or 
COPD (19), we should determine whether a conventional MR 
contrast agent may be preferred over gadoxetate disodium 
by weighing the benefits of the hepatobiliary phase, i.e., 
high lesion-to-liver contrast against the risk of TSM. The 
use of multiple arterial-phase acquisition or new motion-
resistant sequences would help to mitigate the effects of 
TSM on arterial-phase images. For a better depiction of 
arterial hypervascularity of lesions, either 3T or subtraction 
techniques are favored. 
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